Natixis Advisors LLC Purchases 35,043 Shares of Humana Inc. (NYSE:HUM)

Natixis Advisors LLC lifted its position in Humana Inc. (NYSE:HUM) by 36.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 131,418 shares of the insurance provider’s stock after purchasing an additional 35,043 shares during the quarter. Natixis Advisors LLC owned about 0.11% of Humana worth $33,342,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HUM. Harbour Investments Inc. increased its holdings in shares of Humana by 48.6% in the third quarter. Harbour Investments Inc. now owns 642 shares of the insurance provider’s stock worth $203,000 after purchasing an additional 210 shares during the last quarter. CIBC Asset Management Inc increased its stake in Humana by 7.7% during the third quarter. CIBC Asset Management Inc now owns 17,755 shares of the insurance provider’s stock worth $5,624,000 after acquiring an additional 1,274 shares during the last quarter. Empowered Funds LLC increased its stake in Humana by 164.0% during the third quarter. Empowered Funds LLC now owns 14,914 shares of the insurance provider’s stock worth $4,724,000 after acquiring an additional 9,264 shares during the last quarter. Kinsale Capital Group Inc. increased its stake in Humana by 21.2% during the third quarter. Kinsale Capital Group Inc. now owns 11,777 shares of the insurance provider’s stock worth $3,730,000 after acquiring an additional 2,062 shares during the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in Humana by 12.4% during the third quarter. Mutual of America Capital Management LLC now owns 21,717 shares of the insurance provider’s stock worth $6,879,000 after acquiring an additional 2,395 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Stock Up 0.5 %

Humana stock opened at $253.11 on Monday. The business has a fifty day moving average of $271.37 and a two-hundred day moving average of $279.50. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $30.55 billion, a P/E ratio of 25.44, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana’s dividend payout ratio is presently 35.58%.

Analyst Ratings Changes

Several brokerages have weighed in on HUM. JPMorgan Chase & Co. reduced their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, Barclays upped their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.